THY1 and neoplasm: To investigate whether CD90+HepG2/DC-CTLs against CSCs may inhibit HepG2 cell-induced tumor growth in vivo, CD90+HepG2/DC-CTLs, HepG2/DC-CTLs, mDC-CTLs, and DC-CTLs were injected into nude mice subcutaneously mixed with HepG2 cells.